View in EDS HTML Full Text PDF Full Text

Results from a Phase 1/2 trial of BB2603, a terbinafine‐based topical nano‐formulation, in onychomycosis and tinea pedis.

Saved in:
Bibliographic Details
Title: Results from a Phase 1/2 trial of BB2603, a terbinafine‐based topical nano‐formulation, in onychomycosis and tinea pedis.
Authors: Fuhr, Rainard1 (AUTHOR), Cook, David2 (AUTHOR), Ridden, John2 (AUTHOR), Nield, Kerry2 (AUTHOR), Leigh, Emma2 (AUTHOR) emma.leigh@blueberrytherapeutics.com, Cook, Julie2 (AUTHOR), Davies‐Strickleton, Heather2 (AUTHOR), Dobmeyer, Juergen2 (AUTHOR)
Source: Mycoses. Jun2022, Vol. 65 Issue 6, p661-669. 9p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:09337407
DOI:10.1111/myc.13448